Do GLP-1 drugs make you lose muscle?
Some, the way any large weight loss does. In the tirzepatide trial’s scan study, about a quarter of the weight people lost was lean mass, the same share as in the placebo group, who lost weight on diet and exercise advice. The drugs cause more loss, so more lean mass goes in pounds. Lifting and protein are how you keep it.
The numbers from the trials
| Drug, trial | People scanned | Fat lost | Lean mass lost | Lean share of the loss |
|---|---|---|---|---|
| Tirzepatide, SURMOUNT-1 | 160 | 33.9% of their fat | 10.9% of their lean mass | about 26% (placebo 25%) |
| Semaglutide, STEP 1 | 140 | 19.3% of their fat | 9.7% of their lean mass | about 38 to 40% |
Lean mass counts everything that isn’t fat or bone, including water, organs and skin, so muscle is only part of it. The 2025 nutrition advisory from four US societies makes the same point.
There’s a hopeful sign too. In SEMALEAN, a year-long study of 106 adults with severe obesity on semaglutide, lean mass fell about 7 pounds (3 kg) by month seven and then held steady, while hand grip strength rose by about 9 pounds (4 kg).
Why it happens
Eating far less means less protein and less fuel coming in, and muscle that isn’t being worked hard is the tissue the body lets go. Lifting on a GLP-1 is like putting a keep sticker on your muscle before the movers arrive.
What to do
- Lift at least two or three days a week. The 2025 advisory suggests strength training at least three times a week, plus at least 150 minutes of moderate cardio.
- Eat your protein first at each meal. The advisory suggests about 1.5 g per kg of lean mass, or 80 to 120 grams a day. Under 1.2 g per kg of body weight is too low for most people. Find your range.
- Track strength and waist, not just the scale.
- Talk with your prescriber if you can’t eat enough or you’re losing fast. Never change a dose on your own.
The drug pages have the trial details: Ozempic and Wegovy, Mounjaro and Zepbound.
4 sources
- Look et al., Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight, Diabetes, Obesity and Metabolism, 2025pmc.ncbi.nlm.nih.gov
- Wilding et al., Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study, Journal of the Endocrine Society, 2021pmc.ncbi.nlm.nih.gov
- Mozaffarian et al., Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, American Journal of Clinical Nutrition, 2025pmc.ncbi.nlm.nih.gov
- Alissou et al., Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study, Diabetes, Obesity and Metabolism, 2026pmc.ncbi.nlm.nih.gov